FOLH1 and metastatic prostate carcinoma: One recent review of 17 clinical studies with [177Lu]Lu-PSMA-617 therapy for the treatment of progressive metastatic prostate cancer reported that the majority of patients responded to the PSMA-targeted radionuclide therapy and the survival was found to be upwards of one year [50].